Despite the expanding literature on treatment disparities in metastatic breast cancer, few studies have specifically examined the factors influencing the use of HER2-targeted therapies in patients with metastatic HR−/HER2+ breast cancer. This evidence concerns the gene ERBB2 and breast carcinoma.